Literature DB >> 26766887

Pharmaceutical Approval Update.

Chris Fellner.   

Abstract

Elotuzumab (Empliciti) and ixazomib (Ninlaro) for some multiple myeloma patients; Fluad (influenza vaccine, adjuvanted) for immunization of persons 65 years of age and older; and osimertinib (Tagrisso) for certain non-small-cell lung cancers.

Entities:  

Year:  2016        PMID： 26766887      PMCID： PMC4699482     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

Review 1.  Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.

Authors:  Xiaochun Wang; David Goldstein; Philip J Crowe; Jia-Lin Yang
Journal:  Onco Targets Ther       Date:  2016-09-06       Impact factor: 4.147

Review 2.  Current Challenges in Vaccinology.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Peter Palese; Gregory A Poland
Journal:  Front Immunol       Date:  2020-06-25       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.